ZA200706349B - Poly(ethylene glycol)-modified human growth hormone and use thereof - Google Patents

Poly(ethylene glycol)-modified human growth hormone and use thereof

Info

Publication number
ZA200706349B
ZA200706349B ZA200706349A ZA200706349A ZA200706349B ZA 200706349 B ZA200706349 B ZA 200706349B ZA 200706349 A ZA200706349 A ZA 200706349A ZA 200706349 A ZA200706349 A ZA 200706349A ZA 200706349 B ZA200706349 B ZA 200706349B
Authority
ZA
South Africa
Prior art keywords
growth hormone
human growth
poly
modified human
hgh
Prior art date
Application number
ZA200706349A
Other languages
English (en)
Inventor
Rory F Finn
Original Assignee
Pharmacia Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34886516&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ZA200706349(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pharmacia Corp filed Critical Pharmacia Corp
Publication of ZA200706349B publication Critical patent/ZA200706349B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/27—Growth hormone [GH], i.e. somatotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/46—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of glucocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/61—Growth hormone [GH], i.e. somatotropin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Molecular Biology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Urology & Nephrology (AREA)
ZA200706349A 2004-02-04 2005-01-24 Poly(ethylene glycol)-modified human growth hormone and use thereof ZA200706349B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US10/771,895 US20040142870A1 (en) 2002-11-20 2004-02-04 N-terminally monopegylated human growth hormone conjugates, process for their preparation, and methods of use thereof

Publications (1)

Publication Number Publication Date
ZA200706349B true ZA200706349B (en) 2008-06-25

Family

ID=34886516

Family Applications (2)

Application Number Title Priority Date Filing Date
ZA200706349A ZA200706349B (en) 2004-02-04 2005-01-24 Poly(ethylene glycol)-modified human growth hormone and use thereof
ZA200606375A ZA200606375B (en) 2004-02-04 2006-08-01 N-terminally monopegylated human growth hormone conjugates, process for their preparation, and methods of use thereof

Family Applications After (1)

Application Number Title Priority Date Filing Date
ZA200606375A ZA200606375B (en) 2004-02-04 2006-08-01 N-terminally monopegylated human growth hormone conjugates, process for their preparation, and methods of use thereof

Country Status (21)

Country Link
US (1) US20040142870A1 (fr)
EP (2) EP1915999A1 (fr)
JP (3) JP2007520544A (fr)
KR (2) KR100776862B1 (fr)
CN (1) CN1929857A (fr)
AT (1) ATE365047T1 (fr)
AU (1) AU2005215250A1 (fr)
BR (1) BRPI0507427A (fr)
CA (1) CA2555772A1 (fr)
CY (1) CY1106723T1 (fr)
DE (1) DE602005001445T2 (fr)
DK (1) DK1715887T3 (fr)
ES (1) ES2286787T3 (fr)
IL (1) IL176998A0 (fr)
NO (1) NO20063926L (fr)
PL (1) PL1715887T3 (fr)
PT (1) PT1715887E (fr)
RU (1) RU2006128293A (fr)
TW (2) TW200529868A (fr)
WO (1) WO2005079838A1 (fr)
ZA (2) ZA200706349B (fr)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030171285A1 (en) * 2001-11-20 2003-09-11 Finn Rory F. Chemically-modified human growth hormone conjugates
BR0314172A (pt) 2002-09-09 2005-07-26 Nektar Therapeutics Al Corp Polìmero solúvel em água, composição, forma de hidrato ou acetal, composto,composição, usos do composto e do conjugado, e, processo para preparar o conjugado
CA2498319A1 (fr) * 2002-09-09 2004-03-18 Nautilus Biotech Evolution rationnelle de cytokines pour une plus grande stabilite, les cytokines et molecules d'acide nucleique codant
US20040142870A1 (en) * 2002-11-20 2004-07-22 Finn Rory F. N-terminally monopegylated human growth hormone conjugates, process for their preparation, and methods of use thereof
BR0317742A (pt) * 2002-12-26 2005-11-22 Mountain View Pharmaceuticals Conjugados poliméricos de interferon-beta com potência biológica aumentada
WO2004060300A2 (fr) * 2002-12-26 2004-07-22 Mountain View Pharmaceuticals, Inc. Conjugues polymeres de cytokines, de chimiomokines, de facteurs de croissance, d'hormones polypeptidiques et d'antagonistes de ceux-ci conservant une activite de liaison aux recepteurs
CA2576915A1 (fr) * 2004-08-18 2006-03-02 Elixir Pharmaceuticals, Inc. Secretagogues d'hormone de croissance
WO2006018428A2 (fr) * 2004-08-20 2006-02-23 Novo Nordisk A/S Proteines hybrides d'hemopexine
US7998930B2 (en) 2004-11-04 2011-08-16 Hanall Biopharma Co., Ltd. Modified growth hormones
WO2006084888A2 (fr) 2005-02-10 2006-08-17 Novo Nordisk A/S Hormones de croissance pegylees a leur extremite c
EP1861125A2 (fr) * 2005-03-23 2007-12-05 Nektar Therapeutics Al, Corporation Conjugues d'un fragment de hgh et d'un polymere
US7855279B2 (en) 2005-09-27 2010-12-21 Amunix Operating, Inc. Unstructured recombinant polymers and uses thereof
US20080299072A1 (en) * 2005-12-15 2008-12-04 Laboratoires Serono Sa Chemokine Antagonists
AU2007267798A1 (en) * 2006-05-26 2007-12-06 Ipsen Pharma S.A.S. Methods for site-specific pegylation
CA2720306C (fr) * 2008-04-03 2016-03-15 Biosteed Gene Expression Tech. Co., Ltd. Hormone de croissance modifiee par polyethyleneglycol double brin, son procede de preparation et son application
EP2113256A1 (fr) 2008-04-29 2009-11-04 Ascendis Pharma AS Dérivés pégylés du rhGH
PT3050576T (pt) * 2008-04-29 2021-06-01 Ascendis Pharma Growth Disorders Div A/S Compostos recombinantes e peguilados da hormona de crescimento humana
MY156568A (en) * 2008-07-31 2016-03-15 Pharmaessentia Corp Peptide-polymer conjugates
US8680050B2 (en) * 2009-02-03 2014-03-25 Amunix Operating Inc. Growth hormone polypeptides fused to extended recombinant polypeptides and methods of making and using same
DK2393828T3 (en) 2009-02-03 2017-01-23 Amunix Operating Inc Extended recombinant polypeptides and compositions comprising same
US8703717B2 (en) 2009-02-03 2014-04-22 Amunix Operating Inc. Growth hormone polypeptides and methods of making and using same
US9849188B2 (en) 2009-06-08 2017-12-26 Amunix Operating Inc. Growth hormone polypeptides and methods of making and using same
WO2011018515A1 (fr) * 2009-08-14 2011-02-17 Novo Nordisk Health Care Ag Procédé de purification de protéines pegylées
DK2512450T3 (en) 2009-12-15 2018-04-23 Ascendis Pharma Endocrinology Div A/S Dry growth hormone composition transiently bound to a polymer carrier
CN102453089B (zh) * 2010-10-25 2014-06-04 北京凯因科技股份有限公司 重组集成干扰素变异体聚乙二醇偶联物的制备和应用
ES2764106T3 (es) * 2011-12-09 2020-06-02 Metabolic Pharmaceuticals Pty Ltd Uso de fragmentos de la hormona del crecimiento
CN102964588A (zh) * 2012-11-09 2013-03-13 河南工业大学 末端连接氨基苯丙酸的聚乙二醇的酸或活性酯的制法和应用
KR101599415B1 (ko) 2015-05-29 2016-03-03 (주)신명이앤씨 건축물 층간 바닥 전기 케이블 보호관
CN114539384A (zh) * 2020-11-19 2022-05-27 江苏众红生物工程创药研究院有限公司 聚乙二醇化长效生长激素及其制备方法和医药应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005525302A (ja) * 2001-11-20 2005-08-25 ファルマシア・コーポレーション 化学的に修飾されたヒト成長ホルモンコンジュゲート
US20040142870A1 (en) * 2002-11-20 2004-07-22 Finn Rory F. N-terminally monopegylated human growth hormone conjugates, process for their preparation, and methods of use thereof

Also Published As

Publication number Publication date
BRPI0507427A (pt) 2007-06-26
JP2008037872A (ja) 2008-02-21
JP2007520544A (ja) 2007-07-26
JP2008001713A (ja) 2008-01-10
ZA200606375B (en) 2007-11-28
US20040142870A1 (en) 2004-07-22
EP1715887B1 (fr) 2007-06-20
DK1715887T3 (da) 2007-09-17
ATE365047T1 (de) 2007-07-15
TW200812610A (en) 2008-03-16
RU2006128293A (ru) 2008-02-10
ES2286787T3 (es) 2007-12-01
PT1715887E (pt) 2007-08-29
KR20060120240A (ko) 2006-11-24
NO20063926L (no) 2006-10-30
EP1715887A1 (fr) 2006-11-02
IL176998A0 (en) 2006-12-10
TW200529868A (en) 2005-09-16
CA2555772A1 (fr) 2005-09-01
CY1106723T1 (el) 2012-05-23
PL1715887T3 (pl) 2007-12-31
DE602005001445T2 (de) 2008-02-14
KR20070039623A (ko) 2007-04-12
AU2005215250A1 (en) 2005-09-01
WO2005079838A1 (fr) 2005-09-01
CN1929857A (zh) 2007-03-14
EP1915999A1 (fr) 2008-04-30
DE602005001445D1 (de) 2007-08-02
KR100776862B1 (ko) 2007-11-28

Similar Documents

Publication Publication Date Title
ZA200706349B (en) Poly(ethylene glycol)-modified human growth hormone and use thereof
MX344559B (es) Compuestos de hormona de crecimiento humana recombinante unidos al peg.
AP2004003050A0 (en) Chemically modified human growth hormone conjugates
TW200501983A (en) Uses of anti-insulin-like growth factor I receptor antibodies
ATE450269T1 (de) Peptid pyyä3-36ü zur behandlung von stoffwechselkrankheiten
MY158627A (en) Halogen-stabilized insulin
MXPA05004993A (es) Conjugados de hormona del crecimiento humana modificados quimicamente.
WO2003096990A3 (fr) Cages proteiques pour l'administration d'agents therapeutiques et d'imagerie medicale
WO2005078124A3 (fr) Marqueur diagnostique pour le cancer
WO2006034373A3 (fr) Variants et variants chimiquement modifies de phenylalanine ammonia-lyase
TW200621291A (en) Glycerol branched polyethylene glycol human growth hormone conjugates, process for their preparation, and methods of use thereof
EP2107071A3 (fr) Iimmunoglobulines anti-epcam
MY146351A (en) Compositions for treating infection in cattle and swine
TNSN07191A1 (en) Antiangiogenesis therapy of autoimmune disease in patients who have failed prior therapy
WO2006114105A3 (fr) Methodes permettant de traiter les saignements
WO2008142303A3 (fr) Utilisation d'un anticorps anti-cxcr4 pour le traitement du cancer
EP1544214A4 (fr) Anticorps anti-apc non neutralisant
AU2003240790A1 (en) Antibody peg positional isomers, compositions comprising same, and use thereof
JOP20200046A1 (ar) طرق لعلاج أمراض مرتبطة بـtnf?
EP1760087A4 (fr) Nouveau complexe proteinique et utilisation de ce complexe
WO2004050703A8 (fr) Variant d'epissage de l'hormone de croissance hypophysaire humaine
WO2007005995A3 (fr) Compositions pour administration par voie buccale de l'hormone de croissance humaine
WO2003106666A3 (fr) Variants de la proteine c presentant des proprietes modifiees
WO2006012525A3 (fr) Therapie non-diabetogenique faisant intervenir un variant d'hormone de croissance placentaire 20kda
TW200519078A (en) 2-alkylidene-19-nor-vitamin d derivatives for the treatment of a second hip fracture